Adalimumab and infliximab impair SARS-CoV-2 antibody responses: results from a therapeutic drug monitoring study in 11422 biologic-treated patients.

Neil ChanchlaniSimeng LinDesmond CheeBenjamin HamiltonRachel NiceArkir ZehraClaire BewsheaBessie CiprianoLauranne A A P DerikxAllan DunlopLouise GreatheadRachel L GriffithsHajir IbraheimPeter KelleherKlaartje B KokCharlie W LeesJonathan MacDonaldShaji SebastianPhilip J SmithTimothy J McDonaldPeter M IrvingNick PowellNicholas A KennedyJames R GoodhandTariq Ahmad

Published in: Journal of Crohn's & colitis (2021)

Anti-TNF treatment is associated with lower SARS-CoV-2 nucleocapsid seroprevalence and antibody reactivity when compared to vedolizumab-treated patients. Higher seropositivity rates in patients with undetectable anti-TNF levels supports a causal relationship, although confounding factors, such as combination therapy with immunomodulator, may have influenced the results.

Keyphrases

sars cov
end stage renal disease
rheumatoid arthritis
combination therapy
chronic kidney disease
prognostic factors
peritoneal dialysis
respiratory syndrome coronavirus